l e t t e r S Activating mutations in genes encoding G protein a (Ga) subunits occur in 4-5% of all human cancers 1 , but oncogenic alterations in Gb subunits have not been defined. Here we demonstrate that recurrent mutations in the Gb proteins GNB1 and GNB2 confer cytokine-independent growth and activate canonical G protein signaling. Multiple mutations in GNB1 affect the protein interface that binds Ga subunits as well as downstream effectors and disrupt Ga interactions with the Gbg dimer. Different mutations in Gb proteins clustered partly on the basis of lineage; for example, all 11 GNB1 K57 mutations were in myeloid neoplasms, and seven of eight GNB1 I80 mutations were in B cell neoplasms. Expression of patientderived GNB1 variants in Cdkn2a-deficient mouse bone marrow followed by transplantation resulted in either myeloid or B cell malignancies. In vivo treatment with the dual PI3K-mTOR inhibitor BEZ235 suppressed GNB1-induced signaling and markedly increased survival. In several human tumors, mutations in the gene encoding GNB1 co-occurred with oncogenic kinase alterations, including the BCR-ABL fusion protein, the V617F substitution in JAK2 and the V600K substitution in BRAF. Coexpression of patient-derived GNB1 variants with these mutant kinases resulted in inhibitor resistance in each context. Thus, GNB1 and GNB2 alterations confer transformed and resistance phenotypes across a range of human tumors and may be targetable with inhibitors of G protein signaling.
Numerous somatic mutations are present in less than 5% of cases across multiple tumor types. To extensively catalog mutations in these 'long-tail' genes 2 will require sequencing thousands of additional specimens from each tumor subset, a daunting challenge for rare malignancies 3 . A fraction of mutations in long-tail genes are 'gain of function' and may represent tractable therapeutic targets, confer resistance to particular agents or underlie "exceptional responses" 4 . The timely identification of clinically actionable mutations is particularly pressing, as focused sequencing panels to guide targeted therapeutics are becoming widely used.
To functionally interrogate tumors for gain-of-function alterations, we constructed retroviral cDNA libraries from individual cancers and transduced them into cytokine-dependent cells, such as murine BaF3 cells that express the antiapoptotic protein BCL2 (BaF3-BCL2) or the MYC oncogene (BaF3-MYC) 5, 6 . In this system, oncogenic variants of EGFR, FLT3, RAS and ALK resulting from single nucleotide, insertion or deletion, splice-variant or gene fusion alterations confer cytokine-independent growth 6 . We then isolated proliferating clones and sequenced the integrated cDNA ( Fig. 1a) .
We constructed a cDNA library from a patient's bone marrow infiltrated with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an acute leukemia subtype with no obviously targetable driver oncogene 7, 8 , and transduced it into BaF3-BCL2 cells. Three independent clones capable of growth in the absence of IL-3 were isolated. All three harbored GNB1 with a lysine-to-glutamic acid substitution at codon 89 (GNB1 K89E). We confirmed that GNB1 K89E also confers IL-3-independent growth in BaF3-MYC cells (Fig. 1b) .
GNB1 encodes a β subunit of heterotrimeric G proteins, which consist of Gα, Gβ and Gγ components that mediate signaling downstream of G protein-coupled receptors 9 . Upon activation, heterotrimeric G proteins dissociate to form two functional molecules:
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance b Flag-GNB1 CDKN2B  IFIT2  IFIT1  IFIT3  SH3BGRL2  IL8  MAN2B2  LGMN  NEU1  INSIG2  PYGL  ARG1  SPRR2A  PON2  PDGFD  GPD2  TMEM56  CCNG2  TESC  LDLR  TFRC  DHCR7  LSS  IDI1  FDFT1  DHCR24  CD55  ABCA7  GUSB  TJP3  KRT23 Low High GNB1 K89E Empty Figure 2 Mutant Gβ proteins lose interaction with Gα subunits and induce activation of PI3K-AKT-mTOR and MAPK pathways. (a) Molecular representation of a heterotrimeric G protein (blue, Gα; red, Gβ; yellow, Gγ) based on a crystal structure (PDB 1GP2) 16 .
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We searched publicly available databases and published reports across all tumor types, and our unpublished sequencing data in hematologic malignancies ( Supplementary Table 1 ) to identify somatic mutations of GNB1 and the closely related family member GNB2. We identified amino acids recurrently altered across multiple tumor types ( Fig. 1c and Supplementary Table 1 ). For example, GNB1 mutations were present in 3 (1.9%) of 157 cases of myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia in one cohort 13 and 5 (0.53%) of 944 cases of MDS in another cohort 14 . Different codon mutations clustered to some extent on the basis of lineage. Most notably, all 11 GNB1 K57 mutations were in myeloid neoplasms compared with one of eight GNB1 I80 mutations (P < 0.001 by two-tailed Fisher's exact test). The remaining seven I80 mutations were in B cell neoplasms ( Fig. 1c) . We confirmed that multiple GNB1 variants conferred cytokine-independent growth in IL-3-dependent lymphoid cells ( Fig. 1d) or granulocyte macrophage colony-stimulating factor (GM-CSF)-dependent TF-1 myeloid cells (Fig. 1e) .
The recurrent mutations affecting residues K57, K78, I80, K89 and M101 are located on the Gβ protein surface that interacts with Gα subunits and downstream effectors 15 (Fig. 2a) . This is similar to recurrently altered residues in the G protein α subunits GNAS (R201 and Q227) and GNAQ and GNA11 (Q209) that are believed to mediate interactions with Gβγ subunits 1, 16 . Immunoprecipitation of wild-type and mutant (K89E) Flag epitope-tagged GNB1 (Flag-GNB1) revealed a 40-kDa species specifically associated with the wild-type protein ( Fig. 2b) . Mass spectrometry analysis of this band detected multiple peptides mapping uniquely to the Gα subunits GNAI2, GNAI3 and GNA11 (Supplementary Table 2 ). Tandem affinity purification-mass spectrometry analysis using stable isotope-labeled amino acids in culture (SILAC) 17 further demonstrated reduced binding of GNB1 K89E, GNB1 I80T and GNB1 K57E to almost all detected Gα subunits but not to Gγ subunits or to the G protein chaperone PDCL 18 ( Fig. 2c and Supplementary Table 3 ). This was confirmed by immunoblotting ( Fig. 2d) . Cell growth promoted by Gβ mutations was not due to liberation of unbound Gα subunits, because treatment with pertussis toxin, which blocks Gα signaling 19, 20 , did not inhibit growth or ERK phosphorylation in cells harboring GNB1 mutations (Supplementary Fig. 1) .
Gβγ activates multiple downstream signaling pathways, including phosphatidylinositol 3-kinase (PI3K) and its downstream signaling proteins AKT and mTOR 21 , MAP kinase (MAPK) 22 and phospholipase Cβ (PLCβ) 23 . As expected, gene-expression profiling and gene-set enrichment analysis (GSEA) 24 showed that signatures of AKT-mTOR-FOXO3, RAS-MAPK and PLCβ pathways from the Molecular Signatures Database of the Broad Institute (MSigDB) were highly enriched in TF-1 cells expressing GNB1 K89E ( Fig. 2e) . Leading edge analysis 24 identified subsets within each signature that contribute most to the enrichment ( Fig. 2f and Supplementary Fig. 2 ). Increased phosphorylation of the PI3K substrate AKT S473; the MAPK signaling proteins MEK S217 and S221; ERK T202 and Y204; and the mTOR substrate P70S6K T389 AKT S473; MEK S217 and S221; ERK T202 and Y204; and P70S6K T389 was confirmed in cells expressing GNB1 mutants ( Fig. 2g) . Phosphoproteomics of SILAC-labeled TF-1 cells expressing wild-type GNB1 or GNB1 K89E identified additional sites with increased phosphorylation in cells expressing GNB1 K89E (Supplementary Tables 4 and 5) .
To determine whether GNB1 mutants promote transformation in vivo, we performed two separate mouse bone marrow transplantation (BMT) experiments. Pretreatment of BMT donors with 5-fluorouracil (5-FU) preferentially induces myeloid malignancies in this assay; in contrast, transduction of bone marrow from untreated donors favors B cell malignancies 25 . Loss of the CDKN2A tumor suppressor locus is frequent in BPDCN 7 and is recurrent among other malignancies with GNB1 mutations 26, 27 . Recipients of Cdkn2a −/− bone marrow from 5-FU-treated donors transduced with GNB1 K57E, I80T or K89E developed a fatal, transplantable myeloid neoplasm beginning approximately 80 d after transplant (Fig. 3a,b and Supplementary Fig. 3 ). Recipients of bone marrow from wild-type donors treated with 5-FU and transduced with GNB1 or GNB1 K89E did not develop any malignancy after 12 months (data not shown). All malignancies from Cdkn2a −/− donors expressed the cell surface markers CD11b, CD11c, CD26, FLT3, CD103 and MHC class II, consistent with a tumor of conventional myeloid dendritic cells ( Fig. 3b and Supplementary Fig. 4) .
When Cdkn2a −/− donors were not pretreated with 5-FU, recipients of marrow transduced with GNB1 I80T or GNB1 K89E developed B cell acute lymphoblastic leukemia with a significantly shorter latency than recipients of bone marrow transduced with empty vector (Supplementary Fig. 5 ). All myeloid and lymphoid neoplasms were transplantable, causing fatal disease in secondary recipients with rapid kinetics (Supplementary Fig. 6a,b) . Furthermore, all GNB1-driven neoplasms with evaluable metaphase cytogenetics showed evidence of clonal chromosomal abnormalities (Supplementary Fig. 6c ).
To interrogate pathway dependencies in GNB1-transformed cells, we screened a panel of 116 small-molecule inhibitors 28 in cells expressing GNB1 K89E. The most potent compounds (with 50% growth inhibitory concentration (IC 50 ) < 30 nM) included a MEK inhibitor (GSK-1120212), catalytic site mTOR inhibitors (PP242, INK-128) and dual PI3K-mTOR inhibitors (BEZ235 and PI-103) ( Supplementary Table 6 ). K562 myeloid leukemia cells expressing GNB1 K89E have increased phosphorylation of targets of mTOR (AKT S473, NDRG1 T346, 4E-BP-1 T37 and T46 and P70S6K T389) (Fig. 3c) . The dual PI3K-mTOR inhibitor BEZ235 and the catalytic mTOR inhibitor AZD8055 suppressed phosphorylation of these substrates. In contrast, the allosteric mTOR inhibitor rapamycin suppressed only P70S6K T389, and the MEK inhibitor U0126 suppressed only ERK T202 and Y204 phosphorylation (Fig. 3c) , which did not differ between K562 cells expressing wild-type GNB1 and those expressing GNB1 K89E.
Because GNB1 K89E activated AKT-mTOR signaling in human leukemia cells, we tested the therapeutic activity of the dual PI3K-mTOR inhibitor BEZ235 in vivo. After transplantation of two independent GNB1 K89E-induced myeloid neoplasms, mice receiving BEZ235 had markedly prolonged survival compared with vehicletreated mice (Fig. 3d) . Treatment with BEZ235 reduced splenomegaly, suppressed PI3K-mTOR signaling and induced apoptosis in neoplastic cells ( Fig. 3e and Supplementary Fig. 7) . Thus, pharmacologic inhibition of PI3K-mTOR signaling represents a promising strategy for targeting GNB1-mutant tumors in vivo.
A recent screen in melanoma cells harboring activating mutations in the MAPK signaling protein BRAF suggested that activation of G protein-coupled receptors by overexpression confers resistance to the BRAF inhibitor vemurafenib 29 . We identified GNB2 K78E in a npg human melanoma (sample ID: MEL-JWCI-WGS-6) 30 that harbored a V600K substitution in BRAF. Expression of GNB2 K78E in A375 melanoma cells, which harbor BRAF V600E, conferred relative resistance to vemurafenib compared to wild-type GNB1 (Fig. 4a) . These findings raised the possibility that Gβ mutations mediate resistance to a range of kinase inhibitors. We detected GNB1 K89E in a patient with BCR-ABL (p210)-rearranged B cell acute lymphoblastic leukemia who had a poor response to ABL inhibitors. The ABL inhibitors imatinib and nilotinib suppressed phosphorylation of the BCR-ABL substrate STAT5 in K562 cells expressing GNB1 K89E but did not suppress AKT-mTOR signaling (Fig. 4b) . This was associated with relative resistance to nilotinib compared to wild-type GNB1 (Fig. 4c) . In addition, BaF3 cells expressing BCR-ABL with GNB1 K89E, but not with wild-type GNB1, proliferated in the presence of nilotinib (Fig. 4d) .
We identified three myeloid neoplasms with co-occurring mutations in GNB1 and MPL (sample IDs: 08-017857, or JAK2 (sample ID: 08-021722). Expression of GNB1 K89E but not wild-type GNB1 in SET2 myeloid cells, which harbor V617F substitutions in JAK2, conferred relative resistance to the JAK2 inhibitor ruxolitinib (Fig. 4e) . SET2 cells expressing GNB1 K89E, but not wild-type GNB1, proliferated in the presence of ruxolitinib (Fig. 4f) . Similarly, BaF3 cells coexpressing MPL P440L with GNB1 K89E, but not with wildtype GNB1, proliferated in the presence of ruxolitinib (Fig. 4g) .
In summary, oncogenic Gβ alterations occur in multiple cancers, disrupt Gα-Gβγ interactions, activate canonical signaling downstream of G proteins and confer resistance to targeted kinase inhibitors. We distinguished these functionally relevant mutations from the long catalogs of somatic alterations by cDNA library screening. Like mutations in Gα subunits, different Gβ mutations may cluster to some extent within cancer subtypes. Further research is needed to clarify whether differences in signaling downstream of these alleles contribute to context-dependent transformation.
METHODs
Methods and any associated references are available in the online version of the paper.
Accession codes. Gene-expression profiling data have been deposited in Gene Expression Omnibus under accession number GSE60990.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
(electron multiplier detection, 35% normalized collision energy) and higher energy collisionally activated dissociation (image current detection, 25% normalized collision energy) MS/MS scans (isolation width = 2.0 Da). Dynamic exclusion was enabled with a repeat count of 1 and exclusion duration of 20 s. ESI voltage was 2.2 kV.
Data processing. MS/MS spectra were recalibrated using the background ion (Si(CH3)2O)6 at m/z 445.12 ± 0.03, converted into a Mascot generic format (.mgf) using multiplierz scripts 34, 35 and searched with Mascot (version 2.3) against three appended databases consisting of: (i) a forward mouse (for samples generated in BaF3 cells) or human (for samples generated in TF1 cells) protein sequences (both downloaded from RefSeq on 11 July 2011); (ii) common lab contaminants and (iii) a decoy database generated by reversing the sequences of the forward databases. For Mascot searches, precursor mass tolerance was set to 20 ppm and product ion mass tolerance was set to 0.6 Da (CID) or 0.02 Da (HCD, when applicable). Search parameters included trypsin specificity, up to two missed cleavages, fixed carbamidomethylation of cysteine (C, +57 Da), variable oxidation of methionine (M, +16 Da). Variable phosphorylation of serine and threonine (S, T, +80 Da) was also considered for the phosphoproteomics data. Heavy-lysine (+6 Da) and heavy-arginine (+10 Da) were included in the search parameters for SILAC-labeled samples. Spectra matching to peptides from the reverse database were used to calculate a global false discovery rate, and were discarded. Data were further processed to remove peptide spectral matches (PSMs) to the forward database with a false discovery rate (FDR) greater than 1.0%. SILAC intensities for the light and heavy isotopes of each precursor were extracted from raw LC/MS data using custom Python scripts in the multiplierz environment. When necessary (i.e., for gel band analysis), a rapid peptide matching algorithm 36 was used to identify peptide sequences mapping uniquely to a single entry in Entrez Gene. The phosphorylation sites identified across the two biological replicates were matched to the corresponding protein entry in Uniprot.
Clustering analysis. The relative log 10 intensities of each protein in the GNB1 wild-type (WT) and GNB1 mutants (K89E, I80T or K57E) TAP samples were calculated after combining the intensities of their constituent peptides. In the case of GNB1 itself, the intensity of peptides overlapping the mutated site was not included in the ratio calculation. The ratio of wild-type to mutant GNB1 in each TAP was used to normalize the ratio of all interacting proteins. Unsupervised clustering analysis of the normalized relative abundance of G protein subunits and PDCL between the mutant and wild-type GNB1 was performed in R using the heatmap2 package. GNB2, which was only detected by a peptide shared with GNB1, was excluded from this analysis.
Gene-expression profiling and GSEA. Total RNA was extracted in biological triplicates using Trizol from stably transfected TF-1 cells (empty vector control vs. K89E) with or without 12 h cytokine starvation. The quality was assessed using a bioanalyzer and subsequently profiled on an Affymetrix Human Gene ST 1.0 gene chip in the Dana-Farber Microarray Core (http://macf-web.dfci.harvard. edu/). Data processing was performed as previously described 37 . To identify which of pathways are activated in the presence of GNB1 K89E, we selected all known signaling pathways downstream of G proteins ( Supplementary Table 7 ) from the Molecular Signatures Database of the Broad Institute (MSigDB) and tested them for enrichment in the starved GNB1 K89E cells compared to control cells (GNB1 K89E with cytokines, and TF cells transformed with empty vector with and without starvation) using GSEA as previously described 24 . Leading edge genes were visualized using GENE-E (http://www.broadinstitute. org/cancer/software/GENE-E/).
In vivo murine experiments.
All animal experiments were performed with approval of the Dana-Farber Cancer Institute (DFCI) Institutional Animal Care and Use Committee. Mouse bone marrow transplants were performed as previously described 38 . In brief, female FVB mice 8-9 weeks of age were lethally irradiated (5.5 Gy × two doses), and then transplanted with 10 6 donor bone marrow cells (injected intravenously (i.v.) into the tail vein in a total volume of 200 µl PBS, pH 7.4) that had been transduced with pMSCV GNB1-IRES-GFP (wild-type or mutant) or empty pMSCV-GFP retrovirus. Donor bone marrow was from FVB mice that had or had not been treated 5 d earlier with 150 mg kg −1 5-FU intraperitoneally. Animals were followed daily for signs of illness and when moribund were sacrificed and peripheral blood, bone marrow, and splenocytes were harvested for analysis and cryopreservation. For primary transplantation 10 mice were used per arm for 80% power to detect a 60% difference in survival at a specific time point with α of 0.05. No randomization or blinding was used, and no samples or animals were excluded. To test secondary transplantation, 10 6 splenocytes from a primary leukemic mouse were injected intravenously into sublethally irradiated (5.5 Gy once) FVB wild-type recipients. For treatment trials, after secondary transplantation, mice were randomized into treatment groups to receive vehicle or BEZ235 45 mg kg −1 by oral gavage daily. Days of treatment for each experiment are detailed in figure legends.
Pathologic characterization of malignancies. Flow cytometry to characterized myeloid dendritic cell neoplasms was performed as previously described 39 . Other flow cytometry antibodies included annexin V (Thermo Fisher BDB550475), CD11b (Thermo Fisher BDB552850), CD11c (eBioscience 47-0114-82), CD19 (Thermo Fisher BDB557835), B220 (Thermo Fisher BDB558108), CD43 (Thermo Fisher BDB561856), CD24 (Thermo Fisher BDB560536), BP-1 (eBioscience 12-5891-82), IgM (eBioscience 12-5890-82), and CD127 (Thermo Fisher 17-1271-82). All flow cytometry antibodies were used at 1:200, except for CD19 (1:100), B220 (1:100) and BP-1 (1:50). Immunohistochemistry was performed in the Brigham and Women's histopathology core using a Leica Bone III Autostainer, with the following antibodies: GFP (Abcam ab6556, 1:400), cleaved caspase 3 (Cell Signaling 9664, 1:150), K i -67 (Vector VP-RM04, 1:250), TdT (Dako A3524, 1:25).
Karyotyping. Splenocytes harvested from moribund animals were placed in short-term culture in MarrowMAX (Invitrogen, Carlsbad, CA) medium for 24-72 h. B cell leukemias were supplemented with pokeweed mitogen (PGM, Sigma-Aldrich, St. Louis, MO) at 10 µg ml −1 final concentration. Cultures were treated with colcemid (Irvine Scientific, Santa Ana, CA) at a final concentration of 0.1 µg ml −1 for 3 h, or 0.01 µg ml −1 for overnight exposure. Cells were then exposed to hypotonic 0.075 M KCl for 25 min at 37 °C and fixed with 3:1 methanol/acetic acid. Air-dried slides were made and G-banded following standard GTG banding protocols. Twenty metaphase cells were counted for each successfully analyzed specimen, and 4-6 karyotypes prepared. For clarity, karyotype descriptions are given using International System of Cytogenetic Nomenclature (ISCN) 2013 nomenclature, developed for human but acceptable for mouse chromosome aberrations when whole arm changes are described (MGI Rules for Nomenclature of Chromosome Aberrations, http://www.informatics.jax.org/mgihome/nomen/anomalies. shtml; accessed August 2014).
Small molecule in vitro viability screening. BaF3 cells expressing vector, wildtype, or mutant GNB1 were interrogated against a panel containing graded concentrations of 116 small molecule inhibitors as previously described 28 (for full list of small molecules, see Supplementary Table 6 ). After 3 d, cell viability was assessed using a tetrazolium-based MTS assay (CellTiter Aqueous One Solution Cell Proliferation Assay, Promega). All cell viability values were normalized to the average of control wells containing no drug, and a second order polynomial curve fit was used to calculate IC 50 for each agent.
Patient samples. All participants provided informed written consent for tumor analysis, and all studies were approved by the Dana-Farber Cancer Institute Institutional Review Board.
Statistical methods. Pairwise comparisons were performed using Student's t-test without multiple hypothesis correction, and with *P < 0.05 and **P < 0.01 for mutant protein compared to wild-type unless otherwise noted. Graphs represent mean ± s.d. unless otherwise noted. Survival curves for in vivo experiments were compared using the log-rank test.
Data sets. Gene-expression profiling data are available in GEO with accession number GSE60990. 
